[1]. Dekker, E., Tanis, P. J., Vleugels, J., et al (2019). Colorectal cancer. Lancet (London, England), 394(10207), 1467–1480. https://doi.org/10.1016/S0140-6736(19)32319-0
[2]. Binefa, G., Rodríguez-Moranta, F., Teule, A., et al (2014). Colorectal cancer: from prevention to personalized medicine. World journal of gastroenterology, 20(22), 6786–6808. https://doi.org/10.3748/wjg.v20.i22.6786
[3]. Han, L., Sun, Y., Lu, C., et al (2021). MiR-3614-5p Is a Potential Novel Biomarker for Colorectal Cancer. Frontiers in genetics, 12, 666833. https://doi.org/10.3389/fgene.2021.666833
[4]. Chuang, H. Y., Jiang, J. K., Yang, M. H., et al (2017). Aminopeptidase A initiates tumorigenesis and enhances tumor cell stemness via TWIST1 upregulation in colorectal cancer. Oncotarget, 8(13), 21266–21280. https://doi.org/10.18632/oncotarget.15072
[5]. Bora, K., Bhuyan, M. K., Kasugai, K., et al (2021). Computational learning of
features for automated colonic polyp classification. Scientific reports, 11(1), 4347.
https://doi.org/10.1038/s41598-021-83788-8
[6]. Gires O. (2011). Lessons from common markers of tumor-initiating cells in solid cancers. Cellular and molecular life sciences : CMLS, 68(24), 4009–4022. https://doi.org/10.1007/s00018-011-0772-9
[7]. Chen, W., Liu, Q., Tan, S. Y., et al (2013). Association between carcinoembryonic antigen, carbohydrate antigen 19-9 and body mass index in colorectal cancer patients. Molecular and clinical oncology, 1(5), 879–886. https://doi.org/10.3892/mco.2013.158
[8]. Prensner, J. R., Iyer, M. K., Balbin, O. A., et al (2011). Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nature biotechnology, 29(8), 742–749. https://doi.org/10.1038/nbt.1914
[9]. Du, Z., Fei, T., Verhaak, R. G., et al (2013). Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nature structural & molecular biology, 20(7), 908–913. https://doi.org/10.1038/nsmb.2591
[10]. Wang, S., Chen, Z., Gu, J., et al (2021). The Role of lncRNA PCAT6 in Cancers. Frontiers in oncology, 11, 701495. https://doi.org/10.3389/fonc.2021.701495
[11]. Dong, F., Ruan, S., Wang, J., et al (2020). M2 macrophage-induced lncRNA PCAT6 facilitates tumorigenesis and angiogenesis of triple-negative breast cancer through modulation of VEGFR2. Cell death & disease, 11(9), 728. https://doi.org/10.1038/s41419-020-02926-8
[12]. Luo, Y., Lin, J., Zhang, Y., et al (2020). LncRNA PCAT6 predicts poor prognosis in hepatocellular carcinoma and promotes proliferation through the regulation of cell cycle arrest and apoptosis. Cell biochemistry and function, 38(7), 895–904. https://doi.org/10.1002/cbf.3510
[13]. Zhang, D., Du, D., Yi, S., et al (2020). LncRNA PCAT6: A potential biomarker for diagnosis and prognosis of bladder cancer. Annals of diagnostic pathology, 49, 151642. https://doi.org/10.1016/j.anndiagpath.2020.151642
[14]. Subramanian, A., Tamayo, P., Mootha, V. K., et al (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America, 102(43), 15545–15550. https://doi.org/10.1073/pnas.0506580102
[15]. Yu, G., Wang, L. G., Han, Y., et al (2012). clusterProfiler: an R package for comparing biological themes among gene clusters. Omics : a journal of integrative biology, 16(5), 284–287. https://doi.org/10.1089/omi.2011.0118
[16]. Mootha, V. K., Lindgren, C. M., Eriksson, K. F., et al (2003). PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature genetics, 34(3), 267–273. https://doi.org/10.1038/ng1180
[17]. Barbie, D. A., Tamayo, P., Boehm, J. S., et al (2009). Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature, 462(7269), 108–112. https://doi.org/10.1038/nature08460
[18]. Bindea, G., Mlecnik, B., Tosolini, M., et al (2013). Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity, 39(4), 782–795. https://doi.org/10.1016/j.immuni.2013.10.003
[19]. Shi, S. B., Cheng, Q. H., Gong, S. Y., et al (2021). PCAT6 may be a new prognostic biomarker in various cancers: a meta-analysis and bioinformatics analysis. Cancer cell international, 21(1), 370. https://doi.org/10.1186/s12935-021-02079-4
[20]. Wu, K., Feng, Q., Li, L., et al (2020). Long-Noncoding RNA PCAT6 Aggravates Osteosarcoma Tumourigenesis via the MiR-143-3p/ZEB1 Axis. OncoTargets and therapy, 13, 8705–8714. https://doi.org/10.2147/OTT.S258415
[21]. Tu, J., Wu, F., Chen, L., et al (2021). Long Non-Coding RNA PCAT6 Induces M2 Polarization of Macrophages in Cholangiocarcinoma via Modulating miR-326 and RhoA-ROCK Signaling Pathway. Frontiers in oncology, 10, 605877. https://doi.org/10.3389/fonc.2020.605877
[22]. Yu, J., Hua, R., Zhang, Y., et al (2020). DNA hypomethylation promotes invasion and metastasis of gastric cancer cells by regulating the binding of SP1 to the CDCA3 promoter. Journal of cellular biochemistry, 121(1), 142–151. https://doi.org/10.1002/jcb.28993
[23]. Xu, Y., Qin, L., Sun, T., et al (2017). Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression. Oncogene, 36(8), 1157–1166. https://doi.org/10.1038/onc.2016.286
[24]. Ma, C., Wang, F., Han, B., et al (2018). SALL1 functions as a tumor suppressor in breast cancer by regulating cancer cell senescence and metastasis through the NuRD complex. Molecular cancer, 17(1), 78. https://doi.org/10.1186/s12943-018-0824-y
[25]. Lee, S., & Lee, J. S. (2019). Cellular senescence: a promising strategy for cancer therapy. BMB reports, 52(1), 35–41. https://doi.org/10.5483/BMBRep.2019.52.1.294
[26]. Sak, A., Groneberg, M., & Stuschke, M. (2019). DNA-dependent protein kinase: effect on DSB repair, G2/M checkpoint and mode of cell death in NSCLC cell lines. International journal of radiation biology, 95(9), 1205–1219. https://doi.org/10.1080/09553002.2019.1642536
[27]. Grundy, G. J., & Parsons, J. L. (2020). Base excision repair and its implications to cancer therapy. Essays in biochemistry, 64(5), 831–843. https://doi.org/10.1042/EBC20200013
[28]. Kong, F. R., Lv, Y. H., Yao, H. M., et al (2019). LncRNA PCAT6 promotes occurrence and development of ovarian cancer by inhibiting PTEN. European review for medical and pharmacological sciences, 23(19), 8230–8238.
https://doi.org/10.26355/eurrev_201910_19132
[29]. Xin, Y., He, X., Zhao, W., et al (2019). LncRNA PCAT6 increased cholangiocarcinoma cell proliferation and invasion via modulating miR-330-5p. American journal of translational research, 11(9), 6185–6195.
[30]. Liu, P., Zhao, P., Li, B., et al (2020). LncRNA PCAT6 Regulated by YY1 Accelerates the Progression of Glioblastoma via miR-513/IGF2BP1. Neurochemical research, 45(12), 2894–2902. https://doi.org/10.1007/s11064-020-03138-4
[31]. Mahmoud, A. M., & Ali, M. M. (2019). Methyl Donor Micronutrients that Modify DNA Methylation and Cancer Outcome. Nutrients, 11(3), 608. https://doi.org/10.3390/nu11030608
[32]. Zafon, C., Gil, J., Pérez-González, B., et al (2019). DNA methylation in thyroid cancer. Endocrine-related cancer, 26(7), R415–R439. https://doi.org/10.1530/ERC-19-0093
[33]. Hata, A., & Lieberman, J. (2015). Dysregulation of microRNA biogenesis and gene silencing in cancer. Science signaling, 8(368), re3. https://doi.org/10.1126/scisignal.2005825